All questionsPharmacology: Verzenio (abemaciclib), all indications6 questions · 2 sourcesMechanismHow does Verzenio work (mechanism of action)?“Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size.” (opens the source at this quote in a new tab)CopyFlagWhat does Lilly report about Verzenio CDK4 versus CDK6 selectivity?“Verzenio has a chemical structure that is 14x more selective for CDK4 than for CDK62” (opens the source at this quote in a new tab)CopyFlagNote: The selectivity statement on the mechanism of action page of the Verzenio HCP site cites a preclinical characterization study (Gelbert et al., Invest New Drugs 2014).PharmacokineticsHow is Verzenio metabolized and eliminated?“Hepatic metabolism is the main route of clearance for abemaciclib. Abemaciclib is metabolized to several metabolites primarily by cytochrome P450 (CYP) 3A4, with formation of N-desethylabemaciclib (M2) representing the major metabolism pathway. Additional metabolites include hydroxyabemaciclib (M20), hydroxy-N-desethylabemaciclib (M18), and an oxidative metabolite (M1). M2, M18, and M20 are equipotent to abemaciclib and their AUCs accounted for 25%, 13%, and 26% of the total circulating analytes in plasma, respectively.” (opens the source at this quote in a new tab)CopyFlag“After a single 150 mg oral dose of radiolabeled abemaciclib, approximately 81% of the dose was recovered in feces and approximately 3% recovered in urine. The majority of the dose eliminated in feces was metabolites.” (opens the source at this quote in a new tab)CopyFlagWhat is the half-life of Verzenio?“The geometric mean hepatic clearance (CL) of abemaciclib in patients was 26.0 L/h (51% CV), and the mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV).” (opens the source at this quote in a new tab)CopyFlag“Steady state was achieved within 5 days following repeated twice daily dosing, and the estimated geometric mean accumulation ratio was 2.3 (50% CV) and 3.2 (59% CV) based on Cmax and AUC, respectively.” (opens the source at this quote in a new tab)CopyFlag“The median Tmax of abemaciclib is 8.0 hours (range: 4.1-24.0 hours).” (opens the source at this quote in a new tab)CopyFlagDoes Verzenio reach the cerebrospinal fluid?“In patients with advanced cancer, including breast cancer, concentrations of abemaciclib and its active metabolites M2 and M20 in cerebrospinal fluid are comparable to unbound plasma concentrations.” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the inactive ingredients in Verzenio?“VERZENIO (abemaciclib) tablets are provided as immediate-release oval white, beige, or yellow tablets. Inactive ingredients are as follows: Excipients—microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide. Color mixture ingredients—polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, and iron oxide red.” (opens the source at this quote in a new tab)CopyFlag